Old asthma drug shows promise for rare genetic disorder
NCT ID NCT03029429
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether theophylline, a drug used for asthma, can help people with pseudohypoparathyroidism lose weight and improve blood sugar control. The study includes 29 obese participants aged 13 and older. Researchers will measure changes in body mass index and glucose tolerance over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- theophylline
- What this could lead to
- If successful, this could point toward a new treatment to help manage weight and blood sugar in people with pseudohypoparathyroidism.
- What could go wrong
- This is a small early-phase trial with only 29 participants, so results may not apply to everyone. Theophylline can cause side effects like nausea or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALBRIGHT HEREDITARY OSTEODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jaclyn Tamaroff
Nashville, Tennessee, 37212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Long-Term study sheds light on rare bone and hormone disorder
- Why are people with this rare bone disorder prone to diabetes?
- 2000-Patient study aims to uncover hidden metabolic risks in rare genetic disorders
- Could a common asthma drug help treat a rare genetic disorder?
- Old asthma drug could help kids with rare bone and hormone disorder
- Massive study aims to unlock secrets of parathyroid diseases